Cytotoxicity induced by inhibition of thioredoxin reductases via multiple signaling pathways: Role of cytosolic phospholipase A2α- dependent and -independent release of arachidonic acid

Journal of Cellular Physiology

Volumn 219, Issue 3, 2009, Pages 606-616

  Kurosawa, Takeshi ^a   Nakamura, Hiroyuki ^a   Yamaura, Erika ^a   Fujino, Hiromichi ^a   Matsuzawa, Yasuo ^b   Kawashima, Tatsuo ^b   Murayama, Toshihiko ^a  

^a CHIBA UNIVERSITY   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ARACHIDONIC ACID; AURANOFIN; BUTYLATED HYDROXYANISOLE; CYTOSOLIC PHOSPHOLIPASE A2; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; REACTIVE OXYGEN METABOLITE; THIOREDOXIN REDUCTASE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4-(4-FLUOROPHENYL)-2-(4-HYDROXYPHENYL)-5-(4-PYRIDYL)IMIDAZOLE; APOPTOSIS SIGNAL REGULATING KINASE 1; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; PHOSPHOLIPASE A2 GROUP IV; PYRIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; PYRROPHENONE;

ANIMAL CELL; ANIMAL CELL CULTURE; APOPTOSIS; ARTICLE; CELL DEATH; CELL STRAIN L 929; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FIBROSARCOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG CARCINOMA; MOUSE; NONHUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; ANIMAL; CELL STRAIN; CYTOSOL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

RATTUS;

ANIMALS; ARACHIDONIC ACID; CELL DEATH; CELL LINE, TUMOR; CYTOSOL; DINITROCHLOROBENZENE; ENZYME INHIBITORS; GROUP IV PHOSPHOLIPASES A2; HUMANS; IMIDAZOLES; MAP KINASE KINASE KINASE 5; MAP KINASE SIGNALING SYSTEM; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PC12 CELLS; PYRIDINES; PYRROLIDINES; RATS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 64549144677     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21703     Document Type: Article

References (53)

1. 2α expression by N,N-diethyldithiocarbamate in PC12 cells; involvement of reactive oxygen species and nitric oxide. Toxicol Appl Pharmacol 215:218-227.
2. Anderson ME. 1985. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 113:548-555. (Pubitemid 16195830)
3. Anestål K, Arnér ES. 2003. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J Biol Chem 278:15966-15972. (Pubitemid 36799715)
4. Arnér ESJ, Björnstedt M, Holmgren A. 1995. 1-Chloro-2,4-dinitrobenzene is an irreversible inhibitor of human thioredoxin reductase. J Biol Chem 270:3479-3482.
5. Balboa MA, Balsinde J. 2006. Oxidative stress and arachidonic acid mobilization. Biochim Biophys Acta 1761:385-391. (Pubitemid 43776462)
6. Cenas N, Prast S, Nivinskas H, Sarlauskas J, Arnér ES. 2006. Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells. J Biol Chem 281:5593-5603. (Pubitemid 43847656)
7. Chien PS, Mak OT, Huang HJ. 2006. Induction of COX-2 protein expression by vanadate in A549 human lung carcinoma cell line through EGF receptor and p38 MAPK-mediated pathway. Biochem Biophys Res Commun 339:562-568. (Pubitemid 41739704)
8. Das KC, Das CK. 2000. Thioredoxin, a singlet oxygen quencher and hydroxyl radical scavenger: Redox independent functions. Biochem Biophys Res Commun 277:443-447.
9. Davis W Jr, Ronai Z, Tew KD. 2001. Cellular thiols and reactive oxygen species in drug-induced apoptosis. J Pharmcol Exp Ther 296:1-6. (Pubitemid 32015053)
10. Fujino G, Noguchi T, Takeda K, Ichijo H. 2006. Thioredoxin and protein kinases in redox signaling. Semin Cancer Biol 16:427-435. (Pubitemid 44794596)
11. Gendron MC, Schrantz N, Métivier D, Kroemer G, Maciorowska Z, Sureau F, Koester S, Petit PX. 2001. Oxidation of pyridine nucleotides during Fas- and ceramide-induced apoptosis in Jurkat cells: Correlationwith changes inmitochondria, gluthathione depletion, intracellular acidification and caspase 3 activation. Biochem J 353:357-367. (Pubitemid 32096946)
12. 2. Biol Pharm Bull 27:1168-1173.
13. Holmgren A, Björnstedt M. 1995. Thioredoxin and thioredoxin reductase. Methods Enzymol 252:199-208.
14. Iñarrea P, Moini H, Han D, Rettori D, Aguiló I, Alava MA, Iturralde M, Cadenas E. 2007. Mitochondrial respiratory chain and thioredoxin reductase regulate intermembrane Cu, Zn-superoxide dismutase activity: Implications for mitochondrial energy metabolism and apoptosis. Biochem J 405:173-179. (Pubitemid 46999938)
15. Ishikawa A, Kubota Y, Murayama T, Nomura Y. 1999. Cell death by 1-chloro-2,4-dinitrobenzene, an inhibitor of thioredoxin reductase and its dual regulation by nitric oxide in rats. Neurosci Lett 277:99-102.
16. Jakupoglu C, Przemeck GK, Schneider M, Moreno SG, Mayr N, Hatzopoulos AK, de Angelis MH, Wurst W, Bornkamm GW, Brielmeier M, Conrad M. 2005. Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development. Mol Cell Biol 25:1980-1988. (Pubitemid 40280160)
17. Johansson EB, Chen C, Thorell JO, Fredriksson A, Stone-Elander S, Gafvelin G, Arnér ESJ. 2004. Exploiting the 21st amino acid-purifying and labeling proteins by selenolate targeting. Nat Methods 1:61-66.
18. Kabuyama Y, Kitamura T, Yamaki J, Homma MK, Kikuchi S, Homma Y. 2008. Involvement of thioredoxin reductase 1 in the regulation of redox balance and viability of rheumatoid synovial cells. Biochem Biophys Res Commun 367:491-496.
19. 2 enzymes. Prostaglandin Other Lipid Mediat 68/69:3-58.
20. Lao Q, Kuge O, Fukamachi T, Kakegawa T, Saito H, Nishijima M, Kobayashi H. 2005. An IκB-β COOH terminal region protein is essential for the proliferation of CHO cells under acidic stress. J Cell Physiol 203:186-192. (Pubitemid 40328185)
21. Leroux E, Auzenne E, Weidner D, Wu ZY, Donato NJ, Klostergaard J. 2001. Febrile and acute hyperthermia enhance TNF-induced necrosis of murine L929 fibrosarcoma cells via caspase-regulated production of reactive oxygen intermediates. J Cell Physiol 187:256-263. (Pubitemid 32270084)
22. Leslie CC. 2004. Regulation of the specific release of arachidonic acid by cytosolic phospholipase A2. Prostaglandins Leukot Essent Fatty Acids 70:373-376. (Pubitemid 38429270)
23. Los M, Mozoluk M, Ferrari D, StepczynskaA, Stroh C, Renz A, Herceg Z, Wang ZQ, Schulze-Osthoff K. 2002. Activation and caspase-mediated inhibition of PARP: A molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol Cell 13:978-988. (Pubitemid 34250359)
24. Lu J, Chew EH, Holmgren A. 2007. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA 104:12288-12293. (Pubitemid 47206130)
25. Marzano C, Gandin V, Folda A, Scutari G, Bindolo A, Rigobello MP. 2007. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarial cancer cells. Free Radic Biol Med 42:872-881. (Pubitemid 46274171)
26. Maulik N, Das DK. 2008. Emerging potential of thioredoxin and thioredoxin interacting proteins in various disease conditions. Biochim Biophys Acta 1780:1368-1382.
27. Meuillet EJ, Mahadevan D, Berggren M, Coon A, Powis G. 2004. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding; a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch Biochem Biophys 429:123-133. (Pubitemid 39093822)
28. Nabemoto M, Ohsawa K, Nakamura H, Hirabayashi T, Saito T, Okuma Y, Nomura Y, Murayama T. 2005. Reversible activation of secretory phospholipase A2 by sulfhydryl reagents. Arch Biochem Biophys 436:145-153. (Pubitemid 40332435)
29. Nguyen P, Awwad RT, Smart DDK, Spitz DR, GuisD. 2006. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett 236:164-174.
30. Nordberg J, Arnér ESJ. 2001. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 31:1287-1312. (Pubitemid 33145299)
31. 2α, pyrrophenone. Biochem J 363:727-735.
32. Park SJ, Kim IS. 2005. The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br J Pharmacol 146:506-513.
33. Pennington JD, Jacobs KM, Sun L, Bar-Sela G, Mishra M, Guis D. 2007. Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Curr Pharma Design 13:3368-3377. (Pubitemid 350201671)
34. 2 in arachidonic acid release, phospholipid fatty acid incorporation, and apoptosis in U937 cells responding to hydrogen peroxide. J Biol Chem 279:40385-40391.
35. Pervaiz S, Clément MV. 2002. A permissive apoptotic environment: Function of a decrease in intracellular superoxide anion and cytosolic acidification. Biochem Biophys Res Commun 290:1145-1150. (Pubitemid 34694425)
36. Powis G, Kirkpatrick DL. 2007. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 7:392-397. (Pubitemid 47289261)
37. Rigobello MP, Scutari G, Boscolo R, Bindoli A. 2002. Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. Br J Pharmacol 136:1162-1168.
38. Rigobello MP, Folda A, Dani B, Menabò R, Scutari G, Bindoli A. 2008. Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T cells. Eur J Pharmacol 582:26-34.
39. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, Ichijo H. 1998. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17:2596-2606. (Pubitemid 28221195)
40. Seyfried J, Wüllner U. 2007. Inhibition of thioredoxin reductase induces apoptosis in neuronal cell lines: Role of gluthathione and the MKK4/JNK pathway. Biochem Biophys Res Commun 359:759-764. (Pubitemid 46899014)
41. 2+ ionophores, but not tumor necrosis factor-α. J Pharmacol Sci 96:324-332.
42. 2α-independent pathway. Biochem Pharmacol 75:1358-1369.
43. Takashiro Y, Nakamura H, Koide Y, Nishida A, Murayama T. 2005. Involvement of p38 MAP kinase-mediated cytochrome c release on sphingosine-1-phosphate (S1P)- and N-monomethyl-S1P-induced cell death of PC12 cells. Biochem Pharmacol 70:258-265. (Pubitemid 40814408)
44. Taniguchi T, Shimizu M, Nakamura H, Hirabayashi T, Fujino H, Murayama T. 2006. Hydrogen peroxide-induced arachidonic acid release in L929 cells; roles of Src, protein kinase C and cytosolic phospholipase A2α. Eur J Pharmacol 546:1-10. (Pubitemid 44331835)
45. Trigona WL, Mullarky IK, Cao Y, Sordillo LM. 2006. Thioredoxin reductase regulates the induction of haem oxygenase-1 expression in aortic endothelial cells. Biochem J 394:207-216. (Pubitemid 43259670)
46. Vercammen D, Brouckaert G, Denecker G, Van de Craen M, Declercq W, Fiers W, Vandenabeele P. 1998. Dual signaling of the Fas receptor: Initiation of both apoptotic and necrotic cell death pathways. J Exp Med 188:919-930. (Pubitemid 28433418)
47. Watson WH, Heilman JM, Hughes LL, Spielberger JC. 2008. Thioredoxin reductase-1 knock down does not result in thioredoxin-1 oxidation. Biochem Biophys Res Commun 368:832-836.
48. 2-linked cascade. J Biol Chem 275:32357-32362.
49. 2 production by rat peritoneal macrophages. Eur J Pharmacol 325:221-227.
50. Yasuda Y, Yoshinaga N, Murayama T, Nomura Y. 1999. Inhibition of hydrogen peroxide-induced apoptosis but not arachidonic acid release in GH3 cell by EGF. Brain Res 850:197-206.
51. Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL. 2006. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 281:13005-13008. (Pubitemid 43855208)
52. Zarubin T, Han J. 2005. Activation and signaling of the p38 MAP kinase pathway. Cell Res 15:11-18. (Pubitemid 41653958)
53. Zhang Y, Shen X. 2007. Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity. Clin Cancer Res 13:2855-2864. (Pubitemid 46849558)